Clinical Trials Browser

Phase 1/2 × Has results × gilteritinib × Clear all

NCT04240002 2026-01-05

A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Phase 1/2 Terminated

9 enrolled 21 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02310321 2025-09-02

A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.

Phase 1/2 Completed

97 enrolled 30 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02014558 2024-12-03

Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1/2 Completed

265 enrolled 80 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03730012 2024-11-29

A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)

Phase 1/2 Completed

11 enrolled 18 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02495233 2024-11-27

A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)

Phase 1/2 Terminated

10 enrolled 18 charts

Carcinoma, Non-Small-Cell Lung

NCT05028751 2024-08-07

A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)

Phase 1/2 Terminated

24 enrolled 19 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute